Drugs for solid cancer: The productivity crisis prompts a rethink

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 767-777

  Rösel, Daniel ^a   Brábek, Jan ^a   Veselý, Pavel ^b   Fernandes, Michael ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^c Medbase   (United States)

Author keywords

Cancer; Drug resistance; Metastasis; Paradigms; Src inhibitors; Translation

Indexed keywords

BOSUTINIB; DASATINIB; DOXORUBICIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; TRASTUZUMAB;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; METASTASIS INHIBITION; NONHUMAN; ONCOGENE SRC; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROSTATE CANCER; SOLID TUMOR; THYROID PAPILLARY CARCINOMA; TUMOR INVASION; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84879924314     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S45177     Document Type: Article

References (115)

1. DeVita VT Jr, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366(23):2207-2214.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
3. Javier RT, Butel JS. The history of tumor virology. Cancer Res. 2008;68(19):7693-7706.
4. Scannell JW, Blanckley A, Boldon H, Warrington B. Opinion: diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191-200.
5. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov. 2011;10(6):428-438.
6. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-715.
7. Fernandes M. Judging a cancer drug: Avastin's story [letter]. New York Times. 2011;160(55423):section A.
8. Brábek J, Fernandes M. Affordable cancer care. Lancet Oncol. 2012;13(1):2-3.
9. Kuhn TS. The Structure of Scientific Revolutions: 50th Anniversary Edition. Chicago: University of Chicago Press; 2012.
10. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-980.
11. Benowitz S. Provocative questions initiative to fund innovative cancer research. J Natl Cancer Inst. 2012:104(13):966-967.
12. Weber GF. Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett. 2013;328(2):207-211.
13. Sleeman JP, Christofori G, Fodde R, et al. Concepts of metastasis in flux: the stromal progression model. Semin Cancer Biol. 2012;22(3): 174-186.
14. Eckhardt BL, Francis PA, Parker BS, Anderson R. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012;11(6):479-497.
15. Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. Eur J Cancer. 2010;46(7):177-180.
16. Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med. 1911;13(4):397-411.
17. Weiss RA, Vogt PK. 100 years of Rous sarcoma virus. J Exp Med. 2011;208(12):2351-2355.
18. Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 1976;260(5547):170-173.
19. Martin GS. The road to Src. Oncogene. 2004;23(48):7910-7917.
20. Becsei-Kilborn E. Scientific discovery and scientific reputation: the reception of Peyton Rous' discovery of the chicken sarcoma virus. J Hist Biol. 2010;43(1):111-157.
21. Canel M, Serrels A, Frame MC, Brunton VG. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci. 2013;126(Pt 2): 393-401.
22. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2012;33(3): 122-128.
23. Sirvent A, Benistant C, Roche S. Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res. 2012;2(4):357-371.
24. Tsuda M, Tanaka S. Roles for Crk in cancer metastasis and invasion. Genes Cancer. 2012;3(5-6):334-340.
25. Elsberger B, Stewart B, Tatarov O, Edwards J. Is Src a viable target for treating solid tumors? Curr Cancer Drug Targets. 2010;10(7): 683-694.
26. Aleshin A, Finn RS. SRC: a century of science brought to the clinic. Neoplasia. 2010;12(8):599-607.
27. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395-406.
28. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2010;17(3):320-329.
29. Box C, Rogers SJ, Mendiola M, Eccles SA. Tumor-microenvironmental interactions: paths to progression and targets for treatment. Semin Cancer Biol. 2010;20(3):128-138.
30. Brábek J, Mierke CT, Rösel D, Veselý P, Fabry B. The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal. 2010;8:22.
31. Loboda A, Nebozhyn MV, Watters JW, et al. EMT is the dominant program in human colon cancer. BMC Med Genomics. 2011;4:9.
32. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21 Suppl 7:S87-S92.
33. Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11(8):573-587.
34. Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012;24(2):277-283.
35. Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer. 2011;11(7):512-522.
36. Cukierman E, Bassi DE. Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors. Semin Cancer Biol. 2010;20(3):139-145.
37. Guck J, Lautenschläger F, Paschke S, Beil M. Critical review: cellular mechanobiology and amoeboid migration. Integr Biol. 2010;2(11-12): 575-583.
38. Panková K, Rösel D, Novotný M, Brábek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci. 2010;67(1):63-71.
39. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009;28(1-2): 113-127.
40. Mierke CT, rösel D, Fabry B, Brábek, J. Contractile forces in tumor cell migration. Eur J Cell Biol. 2008;87(8-9):669-676.
41. Yamaguchi H. Pathological roles of invadopodia in cancer invasion and metastasis. Eur J Cell Biol. 2012;91(11-12):902-907.
42. Saltel F, Daubon T, Juin A, et al. Invadosomes: intriguing structures with promise. Eur J Cell Biol. 2011;90(2-3):100-107.
43. Tolde O, Rosel D, Vesely P, Folk P, Brábek J. The structure of invadopodia in a complex 3D environment. Eur J Cell Biol. 2010;89(9): 674-680.
44. Destaing O, Block MR, Planus E, Albiges-Rizo C. Invadosome regulation by adhesion signaling. Curr Opin Cell Biol. 2011;23(5):597-606.
45. Wang Y, McNiven MA. Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol. 2012;196(3):375-385.
46. Matsui H, Harada I, Sawada Y. Src, p130Cas, and mechanotransduction in cancer cells. Genes Cancer. 2012;3(5-6):394-401.
47. Stylli SS, Kaye AH, Lock P. Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci. 2008;15(7):725-737.
48. Eckert MA, Lwin TM, Chang AT, et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 2011;19(3):372-386.
49. Plé PA, Green TP, Hennequin LF, et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem. 2004;47(4):871-887.
50. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2- methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658-6661.
51. Hennequin LF, Allen J, Breed J, et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy.-5 -(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 2006;49(22):6465-6488.
52. Boschelli DH, Wu B, Barrios Sosa AC, et al. Synthesis and Src kinase inhibitory activity of 2-phenyl-and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles. J Med Chem. 2005;48(11):3891-3902.
53. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007;67(4):1580-1588.
54. Vultur A, Buettner R, Kowolik C, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008;7(5):1185-1194.
55. Green TP, Fennell M, Whittaker R, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. 2009;3(3): 248-261.
56. Pichot CS, Hartig SM, Xia L, et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer. 2009;101(1):38-47.
57. Dong M, Rice L, Lepler S, Pampo C, Siemann DW. Impact of the Src inhibitor Saracatinib on the metastatic phenotype of a fibrosarcoma KHT tumor model. Anticancer Res. 2010;30(11):4405-4413.
58. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-focal adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009;94(6):2199-2203.
59. Chan CM, Jing X, Pike LA, et al. Targeted inhibition of SRC kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012;18(13):3580-3591.
60. Rabbani SA, Valentino ML, Arakelian AS, Boschelli F. SKI-606 (bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther. 2010;9(5):1147-1157.
61. Morton JP, Karim SA, Graham K, et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 2010;139(1):292-303.
62. Ammer AG, Kelley LC, Hayes KE, et al. Saracatinib impairs head and neck squamous cell carcinoma invasion by disrupting invadopodia function. J Cancer Sci Ther. 2009;1(2):52-61.
63. Boyce B, Xing L. Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data. Clin Investig (Lond). 2011;1(12): 1695-1706.
64. Creedon H, Brunton VG. Src kinase inhibitors: promising cancer therapeutics? Crit Rev Oncog. 2012;17(2):145-159.
65. Puls LN, Eadens M, Messersmith W. Current status of Src inhibitors in solid tumor malignancies. Oncologist. 2012;16(5):566-578.
66. Burchill SA. What do, can, and should we learn from models to evaluate potential anticancer agents? Future Oncol. 2006;2(2):201-211.
67. Decaudin D. Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer. Anticancer Drugs. 2011;22(9):827-841.
68. Ocana A, Pandiella A, Siu LL, Tannock IF. Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol. 2011;8(4): 200-209.
69. Caponigro G, Sellers WR. Advances in the preclinical testing of cancer therapeutic hypotheses. Nat Rev Drug Discov. 2011;10(3): 179-187.
70. Teicher BA. In vivo/ex vivo and in situ assays used in cancer research: a brief review. Toxicol Pathol. 2009;37(1):114-122.
71. Céspedes MV, Casanova I, Parreño M, Mangues R. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol. 2006;8(5): 318-329.
72. Singh M, Lima A, Molina R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010;28(6):585-593.
73. Francia G, Kerbel RS. Raising the bar for cancer therapy models. Nat Biotechnol. 2010;28(6):561-562.
74. Robles AI, Varticovski L. Harnessing genetically engineered mouse models for preclinical testing. Chem Biol Interact. 2008;171(12): 159-164.
75. Carver BS, Pandolfi PP. Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res. 2006;12(18):5305-5311.
76. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 2011;11(2):135-141.
77. Baker BM, Chen CS. Deconstructing the third dimension - how 3D culture microenvironments alter cellular cues. J Cell Sci. 2012;125(Pt 13): 3015-3024.
78. Li L, Lu Y. Optimizing a 3D culture system to study the interaction between epithelial breast cancer and its surrounding fibroblasts. J Cancer. 2011;2:458-466.
79. Harunaga JS, Yamada KM. Cell-matrix adhesions in 3D. Matrix Biol. 2011;30(7/8):363-368.
80. Krause S, Maffini MV, Soto AM, Sonnenschein C. The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer. 2010;10:263.
81. Yamada KM, Cukierman S. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007;130(4):601-610.
82. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol. 2006;7(3):211-224.
83. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1. Eur J Cancer. 2009;45(2):228-247.
84. Tuma RS. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst. 2006;98(18):1272-1274.
85. Diederich S. Imaging beyond RECIST: CT and MRI in molecular therapies. Cancer Imaging. 2012;12(2):347-350.
86. Bradbury P, Seymour L. Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point? Cancer J. 2009;15(5):354-360.
87. Goldmacher GV, Conklin J. The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. Br J Clin Pharmacol. 2012;73(6):846-854.
88. Sullivan DC, Gatsonis C. Response to treatment series: part 1 and introduction, measuring tumor response - challenges in the era of molecular medicine. AJR Am J Roentgenol. 2011;197(1):15-17.
89. Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009; 50 Suppl 1:S1-S10.
90. Mozley PM, Bendtsen C, Zhao B, et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol. 2012;5(1):19-25.
91. Birchard KR, Hoang JK, Herndon JE Jr, Patz EF Jr. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer. 2009;115(3): 581-586.
92. Sekine I, Kubota K, Nishiwaki Y, Sasaki Y, Saijo N. Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer. Ann Oncol. 1998;9(10):1079-1084.
93. Weber WA, Czernin J, Phelps ME, Herschman HR. Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol. 2008;5(1): 44-54.
94. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35(4):309-321.
95. Serkova NJ. Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resist Updat. 2011;14(4-5):224-235.
96. Garcia Figuerias R, Padhani AR, Goh VJ, et al. Novel oncologic drugs: what they do and how they affect images. Radiographics. 2011;31(17): 2059-2091.
97. Kang H, Lee HY, Lee KS, Kim JH. Imaging-based tumor treatment response evaluation: review of conventional, new and emerging concepts. Korean J Radiol. 2012;13(4):371-390.
98. Elvin P, Garner AP. Tumor invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol. 2005;5(4):374-381.
99. Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med (Berl). 2008;86(2):135-144.
100. Cooke VG, LeBleu VS, Keskin D, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by MET signaling pathway. Cancer Cell. 2012;21(1): 66-81.
101. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220-231.
102. Ebos JML, Kerbel RS. Antiangiogenic therapy:impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8(4):210-221.
103. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 2012;320(2):130-137.
104. Zhang S, Huang WC, Li P, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011;17(4):461-469.
105. Muthuswamy SK. Trastuzumab resistance: all roads lead to SRC. Nat Med. 2011;17(4):416-418.
106. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med. 2011;364(11):985-987.
107. Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA. 2011;306(23): 2608-2609.
108. Kaiser D. In retrospect: the structure of scientific revolutions. Nature. 2012;484(7393):164-166.
109. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473-480.
110. Lord CJ, Ashworth A. Biology-driven cancer drug development: back to the future. BMC Biol. 2010;8:38.
111. Drews J. Case histories, magic bullets and the state of drug discovery. Nat Rev Drug Discov. 2006;5(8):635-640.
112. Andreeff M, Goodrich DW, Pardee AB. Cell proliferation, differentiation, and apoptosis. In: Bast RC Jr, Kufe DW, Pollock RE, et al, editors. Holland-Frei Cancer Medicine. 5th ed. Hamilton (ON): BC Decker; 2000:17-32.
113. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002;1602(2):114-130.
114. Dyson FJ. Is science mostly driven by ideas or by tools? Science. 2012;338(6113):1426-1427.
115. Drews J. Paul Ehrlich: magister mundi. Nat Rev Drug Discov. 2004;3(9):797-801.